|
Sarcoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Mdm4 in mice drives the spontaneous development of mostly lymphomas and sarcomas.
|
27925213 |
2017 |
|
Sarcoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
In an ex vivo tissue explant system, we found that TP53 pathway alterations (TP53 status, MDM2/MDM4 genomic amplification/mRNA overexpression, MDM2 SNP309, and TP53 SNP72) did not confer apoptotic or cytostatic responses in sarcoma tissue biopsies (n = 24).
|
24336067 |
2014 |
|
Sarcoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
|
24145283 |
2014 |
|
Sarcoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
The aim of our study was to determine the amplification status of the HDMX gene and the expression of the HDMX mRNA (particularly that of the HDMX-S splice variant) in soft-tissue sarcomas (STS).
|
15906355 |
2005 |
|
Sarcoma
|
0.380 |
Biomarker
|
group |
LHGDN |
The aim of our study was to determine the amplification status of the HDMX gene and the expression of the HDMX mRNA (particularly that of the HDMX-S splice variant) in soft-tissue sarcomas (STS).
|
15906355 |
2005 |
|
Sarcoma
|
0.380 |
Biomarker
|
group |
BEFREE |
Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients.
|
12149303 |
2002 |
|
Sarcoma
|
0.380 |
Biomarker
|
group |
BEFREE |
Two independent lines of transgenic mice, Mdm4(Tg1) and Mdm4(Tg15), developed spontaneous tumors, the most prevalent of which were sarcomas.
|
20736370 |
2010 |
|
Sarcoma
|
0.380 |
AlteredExpression
|
group |
BEFREE |
MDM2/4 antagonists, on the other hand, are likely to be efficacious in malignancies in which MDM2 or MDM4 is overexpressed such as sarcomas, neuroblastomas and specific childhood leukemias.
|
25455730 |
2014 |
|
Sarcoma
|
0.380 |
GenomicAlterations
|
group |
CGI |
|
|
|
|
Sarcoma
|
0.380 |
GeneticVariation
|
group |
BEFREE |
Our meta-analysis indicates that the HDMX polymorphism is unlikely to contribute to individual susceptibility to sarcoma.
|
24972690 |
2014 |
|
Mammary Neoplasms
|
0.340 |
AlteredExpression
|
group |
BEFREE |
Noteworthy, MDM4 transcript levels are significantly reduced in breast tumors characterized by high mTOR levels.
|
28270148 |
2017 |
|
Mammary Neoplasms
|
0.340 |
GeneticVariation
|
group |
LHGDN |
Mutation analysis of the MDM4 gene in German breast cancer patients.
|
18279506 |
2008 |
|
Mammary Neoplasms
|
0.340 |
AlteredExpression
|
group |
BEFREE |
Lastly, we report that endogenous MDM4 negatively regulates ERα expression and forms a protein complex with ERα in breast cancer cell lines and primary human breast tumor tissue.
|
26909605 |
2016 |
|
Mammary Neoplasms
|
0.340 |
Biomarker
|
group |
CTD_human |
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
|
23535733 |
2013 |
|
Mammary Neoplasms
|
0.340 |
AlteredExpression
|
group |
LHGDN |
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity.
|
15199139 |
2004 |
|
Cardiomyopathy, Dilated
|
0.200 |
Biomarker
|
group |
MGD |
|
|
|
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this meta-analysis was to evaluate the associations between MDM4 gene polymorphisms and cancer risk.
|
27742919 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of MDM4-B was present in various stages of human gliomas, but no significant correlation between presence of MDM4-B and malignancy of glioma was observed.
|
23994448 |
2013 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To establish whether MRP1 gene copy number is a common feature of the upregulation of MRP1 expression in cancer patients, we studied the MRP1 gene copy number in leukemia patients by fluorescent in situ hybridization (FISH) and real-time PCR.
|
17350479 |
2007 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, screening for p53 activators and a better understanding of the molecular mechanisms of oncogenic perturbations of p53 function have opened up a host of novel avenues for therapeutic intervention in cancer: from the structure-guided design of chemical chaperones to restore the function of conformationally unstable p53 cancer mutants, to the development of potent antagonists of the negative regulators MDM2 and MDMX and other modulators of the p53 pathway for the treatment of cancers with wild-type p53.
|
27145840 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, it may be the basis for developing new, even better, highly potent, less toxic, and selective (as well as broad-spectrum) MRP1 inhibitors that will enter clinical evaluations in different malignancies and finally conduce to overcome MDR in general.
|
29809286 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SIGNIFICANCE: Targeting MDM4 to alleviate degradation of p53 can be exploited therapeutically across Burkitt lymphoma and other cancers with wild-type p53 harboring 1q gain, the most frequent copy number alteration in cancer.
|
31000522 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MRP1 is known for its ability to actively decrease intracellular drug concentration, limiting the efficacy of cancer chemotherapy; however, data on the clinical relevance of MRP1 is inconclusive.
|
30132569 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Role of the MRP1/ABCC1 multidrug transporter protein in cancer.
|
18085475 |
2007 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also explored the impact of MDM4 overexpression on the cell cycle, cell proliferation and the spindle checkpoint of HepG2 cells, which is a human cancer cell line with normal MDM4 and TP53 expression.
|
25405759 |
2014 |